A classic example is resistance to BRAF inhibitors in patients with melanoma, characterized by the paradoxical activation of the MAPK pathway due to increased formation of RAF homo- and hetero-dimers, particularly BRAF-CRAF heterodimers [165,166]. This evidence concerns the gene RAF1 and melanoma.